Teva vows to fight price-fixing lawsuitTeva has said it will defend itself against a lawsuit raised by 44 US states that alleges the Share XTeva vows to fight price-fixing lawsuithttps://pharmaphorum.com/news/teva-vows-to-fight-price-fixing-lawsuit/
Novartis sues as Amgen tries to cancel migraine tie-upNovartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, Share XNovartis sues as Amgen tries to cancel migraine tie-uphttps://pharmaphorum.com/news/novartis-sues-as-amgen-tries-to-cancel-migraine-tie-up/
Teva’s migraine drug Ajovy approved in EuropeTeva’s migraine drug Ajovy (fremanezumab) has been approved in Europe, taking on rivals from the same class from Share XTeva’s migraine drug Ajovy approved in Europehttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-approved-in-europe/
Novo prevents Teva’s Victoza rival launch until 2023Novo Nordisk has settled a US patent case with Teva, which prevents the Israel-based generics firm marketing a Share XNovo prevents Teva’s Victoza rival launch until 2023https://pharmaphorum.com/news/novo-prevents-tevas-victoza-rival-launch-until-2023/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
Teva’s migraine drug Ajovy looks set for EU approvalTeva’s migraine drug Ajovy (fremanezumab) has moved closer to the EU market after the influential CHMP regulatory committee Share XTeva’s migraine drug Ajovy looks set for EU approvalhttps://pharmaphorum.com/news/tevas-migraine-drug-ajovy-looks-set-for-eu-approval/
CVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalUS pharmacy benefits manager CVS Health Corp has added new migraine drugs from Teva and Eli Lilly to Share XCVS covers migraine drugs from Teva and Lilly, excludes Amgen’s rivalhttps://pharmaphorum.com/news/cvs-covers-migraine-drugs-from-teva-and-lilly-excludes-amgens-rival/
Teva and Neos settle over Cotempla patent disputeTeva and Neos Therapeutics have reached a confidential settlement and licensing agreement that resolves a patent dispute over Share XTeva and Neos settle over Cotempla patent disputehttps://pharmaphorum.com/news/teva-and-neos-settle-over-cotempla-patent-dispute/
Celltrion/Teva’s Herceptin biosimilar approved in USThe FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor Share XCelltrion/Teva’s Herceptin biosimilar approved in UShttps://pharmaphorum.com/news/celltrion-tevas-herceptin-biosimilar-approved-in-us/
